In patients with stable coronary artery disease and atrial fibrillation (AF) on oral anticoagulants, adding antiplatelet agents is common and recommended in guidelines, especially during the first year after an acute coronary event or revascularization.
The mortality benefit to percutaneous coronary intervention (PCI) is unquestioned when it comes to ST-elevation myocardial infarction (STEMI).
In patients with severe degenerative mitral regurgitation (MR), surgery is clearly recommended in the presence of any symptoms.
